NikoleV Posted March 20 Share Posted March 20 ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) More info here: https://www.lungevity.org/for-patients-caregivers/navigating-your-diagnosis/participate-in-research/featured-clinical-trials Contact: Marshika Vickers Phone Number: 510-473-2872 Email: marshika_vickers@henlius.com ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) This is a study to learn the effects of the study drug plus chemotherapy on ES-SCLC, compared with atezolizumab combined with chemotherapy. Atezolizumab combined with chemotherapy (etoposide + carboplatin) was approved by the Food and Drug Administration (FDA) in March 2019 in the treatment of ES-SCLC. Who can participate? This study is for adults who: Are 18 years of age and older Have been diagnosed with ES-SCLC Have NOT already received treatment for ES-SCLC Note: If you have received chemotherapy for limited-stage SCLC, it must have taken place more than 6 months before starting this study. Other criteria also apply. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.